- PD 166866
-
- $1.00
-
2019-12-23
- CAS:192705-79-6
- Min. Order: 1g
- Purity: 99.99%
- Supply Ability: 200kg
|
| | PD 166866 Basic information |
| | PD 166866 Chemical Properties |
| Melting point | 291-293°C | | storage temp. | 2-8°C | | solubility | DMSO: ≥10mg/mL | | form | Off-white solid | | color | off-white to light tan | | InChI | 1S/C20H24N6O3/c1-20(2,3)26-19(27)25-17-15(8-12-10-22-18(21)24-16(12)23-17)11-6-13(28-4)9-14(7-11)29-5/h6-10H,1-5H3,(H4,21,22,23,24,25,26,27) | | InChIKey | NHJSWORVNIOXIT-UHFFFAOYSA-N | | SMILES | COc1cc(OC)cc(c1)-c2cc3cnc(N)nc3nc2NC(=O)NC(C)(C)C |
| Hazard Codes | Xn | | Risk Statements | 22 | | WGK Germany | 1 | | Storage Class | 11 - Combustible Solids |
| | PD 166866 Usage And Synthesis |
| Description | PD 166866 is a potent inhibitor of fibroblast growth factor receptor 1 (FGFR1; IC50 = 52.4 nM; Ki = 45.2 nM). It is selective for FGFR1 over PDGFR, EGFR, C-SRC, MEK, PKC, insulin receptor tyrosine kinase, and CDK4 (IC50s = >50 μM). PD 166866 inhibits FGFR1 autophosphorylation in NIH3T3 and L6 cells (IC50s = 10.8 and 3.1 nM, respectively) and inhibits phosphorylation of MAPK (IC50s = 4.3 and 7.9 nM for the 44- and 42-kDa MAPK isoforms, respectively). It reduces FGF- but not EGF- or PDGF-stimulated growth of L6 cells and inhibits microvessel outgrowth from human placental arteries in vitro. PD 166866 inhibits the growth of non-small cell lung cancer (NSCLC) cell lines in a dose-dependent manner and reduces migration of VL-8 cells at a concentration of 10 μM. | | Chemical Properties | Off-White Solid | | Uses | A novel potent ATP competitive pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. An inhibitor of the basic fibroplast growth factor (bFGF). | | Definition | ChEBI: PD-166866 is a member of the class of pyridopyrimidines that is pyrido[2,3-d]pyrimidine substituted by an amino group at position 2, 3,5-dimethoxyphenyl group at position 6, and by a (tert-butylcarbamoyl)nitrilo group at position 7. It is a selective ATP competitive inhibitor of the human fibroblast growth factor-1 receptor (FGFR1) tyrosine kinase with an IC50 of 52.4 nM. It has a role as an apoptosis inducer, an antineoplastic agent, an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor and an angiogenesis inhibitor. It is a dimethoxybenzene, a pyridopyrimidine, a member of ureas, a biaryl and a primary arylamine. | | Biochem/physiol Actions | PD-166866 is a selective inhibitor of the FGF-1 receptor tyrosine kinase (FGFR1) with IC50 = 55 nM, and no effect on c-Src, PDGFR-b, EGFR or insulin receptor tyrosine kinases or MEK, PKC, and CDK4. | | References | [1] R L PANEK. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase.[J]. Journal of Pharmacology and Experimental Therapeutics, 1998, 286 1: 569-577.
[2] HENDRIK FISCHER. Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition.[J]. Molecular Cancer Therapeutics, 2008, 7 10: 3408-3419. DOI: 10.1158/1535-7163.mct-08-0444 |
| | PD 166866 Preparation Products And Raw materials |
|